A2 Biotherapeutics, Inc.
A2 Biotherapeutics, Inc. is a company.
Active
Updated: ·
About
A2 Biotherapeutics, Inc. is a company.
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at A2 Biotherapeutics, Inc..
A2 Biotherapeutics, Inc. is a company.
A2 Biotherapeutics, Inc. is a company.
Key people at A2 Biotherapeutics, Inc..
A2 Biotherapeutics, Inc. (A2 Bio) is a clinical-stage biotechnology company founded in 2018 and headquartered in Agoura Hills/Westlake Village, California, focused on developing precision CAR T-cell therapies for solid tumors and serious illnesses.[1][2][3] The company builds novel logic-gated cell therapies using its proprietary Tmod™ platform, which equips T cells with activator and blocker receptors to precisely target cancer cells while sparing healthy tissue, addressing unmet needs in cancers like pancreatic, lung, colorectal, ovarian, and mesothelioma.[2][3][6] A2 Bio serves patients with difficult-to-treat solid tumors, solving the core challenge of distinguishing tumors from normal cells to improve safety and efficacy of cell therapies.[2][3] Growth momentum includes ongoing Phase 1/2 EVEREST-1 (A2B530 targeting CEA) and EVEREST-2 (A2B694 targeting MSLN) trials, recent data presentations showing initial safety, efficacy, and a complete response in NSCLC, plus an $80 million Series C financing in 2025 to advance three clinical studies and preclinical programs.[1][3][6]
A2 Bio was established in 2018 by a team of scientists leveraging decades of experience in drug discovery across multiple disciplines, who invented the Tmod™ platform through an integrative approach drawing from quantitative methods outside traditional cell therapy.[2][3][4] The idea emerged from addressing the fundamental limitation in cancer treatments—poor discrimination between tumor and normal cells—leading to the creation of a modular, logic-gated system with activator and blocker receptors for precise T-cell targeting.[3][4] Early traction came from preclinical validation of Tmod™ for both autologous and allogeneic applications, rapid progression to clinical trials, and strategic funding, including the recent $80 million Series C to fuel Phase 1/2 studies in high-unmet-need solid tumors.[2][3]
A2 Bio rides the wave of next-generation cell therapies for solid tumors, where traditional CAR T-cells struggle with off-tumor toxicity, by pioneering logic-gated approaches that enhance precision and expand applicability beyond liquid tumors.[2][3] Timing is ideal amid surging demand for targeted immunotherapies, fueled by market forces like aging populations, rising cancer incidence, and investor interest in biotech platforms (e.g., $80M Series C amid CNS therapeutic market projections to $235B by 2033).[1][3] The company influences the ecosystem by validating Tmod™ in real-world trials, potentially setting standards for safer cell therapies and inspiring allogeneic expansions to autoimmune diseases.[2][6]
A2 Bio's near-term path hinges on Phase 1/2 readouts from EVEREST trials, with positive early signals like the NSCLC complete response positioning A2B530/A2B694 for potential Phase 2 acceleration and partnerships.[1][3] Trends in precision oncology, AI-driven target discovery, and allogeneic scaling will shape its trajectory, possibly leading to registrational trials by 2027-2028 if safety/efficacy holds. Influence could evolve from solid tumor pioneer to broader disease modulator, amplifying impact as Tmod™ disrupts CAR T limitations—restoring health for patients where prior therapies fail.[2][3]
Key people at A2 Biotherapeutics, Inc..
